tert-butyl (2S)-2-(1-hydroxyethyl)pyrrolidine-1-carboxylate | 290327-92-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: tert-butyl (2S)-2-(1-hydroxyethyl)pyrrolidine-1-carboxylate
• 英文别名: (2S)-tert-Butyl 2-(1-hydroxyethyl)pyrrolidine-1-carboxylate
• CAS: 290327-92-3
• 化学式: C₁₁H₂₁NO₃
• 分子量: 215.293
• InChiKey: JNNOAQQODYAQBD-GKAPJAKFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl (2S)-2-(1-hydroxyethyl)pyrrolidine-1-carboxylate 在 二异丁基氢化铝 、 三氟乙酸 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 7.0h， 生成 (2E)-2-{[(2S)-2-(1-hydroxyethyl)pyrrolidin-1-yl]methyl}-3-phenylprop-2-en-1-ol
  参考文献：
  名称：

  Pumiliotoxin A 生物碱的研究：通过分子内非对映选择性 N-杂环卡宾催化安息香反应制备 Indolizidinic 核的方法

  摘要：

  在这篇文章中，我们描述了聚合有机催化策略的发展，以制备 pumiliotoxin A 生物碱家族的 indolizidinic 核心。所提出策略的关键步骤是基于非对映选择性 N-杂环卡宾催化的安息香反应，其中由烯醛部分（umpolung a1 到 d1 - 酰基阴离子等价物）生成的 Breslow 中间体在分子内攻击酮部分以提供吲哚里西酮核心收率高，选择性好。

  DOI：

  10.1002/ejoc.201600172
• 作为产物：
  描述：

  二碳酸二叔丁酯 在 pyridine-SO3 complex 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 二甲基亚砜 为溶剂， 生成 tert-butyl (2S)-2-(1-hydroxyethyl)pyrrolidine-1-carboxylate
  参考文献：
  名称：

  4-Phenylbutanoyl-2( S )-acylpyrrolidines and 4-phenylbutanoyl- l -prolyl-2( S )-acylpyrrolidines as prolyl oligopeptidase inhibitors

  摘要：

  New 4-phenylbutanoyl-2(S)-acylpyrrolidines and 4-phenylbutanoyl-L-prolyl-2(S)-acylpyrrolidines were synthesized. Their inhibitory activity against prolyl oligopeptidase from pig brain was tested in vitro. In the series of 4-phenylbutanoyl-2(S)-acylpyrrolidines, the cyclopentanecarbonyl and benzoyl derivatives were the best inhibitors having IC50 values of 30 and 23 nM, respectively. This series of compounds shows that that P1 pyrrolidine ring, which is common in most POP inhibitors, can be replaced by either a cyclopentyl ring or a phenyl ring, causing only a slight decrease in the inhibitory activity. In the series of 4-phenylbutanoyl-L-prolyl-2(S)- acyl-pyrrolidines, the cyclopentanecarbonyl and benzoyl derivatives were not as active as in the series of 4-phenylbutanoyl-2(S)-acylpyrrolidines, The hydroxyacetyl derivative did however show high inhibitors activity. This compound is structurally similar to JTP-4819, which is one of the most potent prolyl oligopeptidase inhibitors. The acyl group in the two series of new compounds seems to bind to different sites of the enzyme, since the second series of ne compounds did not show the same cyclopentanecarbonyl or benzoyl specificity as the first series. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(02)00061-5

文献信息

• [EN] 3-(5-METHOXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS DE 3-(5-MÉTHOXY-1-OXOISOINDOLIN-2-YL)PIPÉRIDINE-2,6-DIONE ET LEURS UTILISATIONS
  申请人：NOVARTIS AG

  公开号：WO2021124172A1

  公开（公告）日：2021-06-24

  The present disclosure relates to compounds of formula (I') and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the treatment of inherited blood disorders (e.g., hemoglobinopathies, e.g., beta-hemoglobinopathies), such as sickle cell disease and beta-thalassemia.

  本公开涉及式(I')的化合物、药物组合物及其在降低广泛间隔锌指蛋白结构域（WIZ）表达水平、诱导胎儿血红蛋白（HbF）表达以及治疗遗传性血液疾病（例如，血红蛋白病，例如，β-血红蛋白病）方面的用途，如镰状细胞病和β-地中海贫血。
• Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3 (2H)-isoquinolones and methods of use thereof
  申请人：Tsou Hwei-Ru

  公开号：US20080085890A1

  公开（公告）日：2008-04-10

  This invention provides compounds of Formula (I), having the structure where G 1 , G 2 , G 3 , G 4 , A 1 , A 2 , Y 1 , Y 2 , L 1 , Z, e and f are defined herein, or a pharmaceutically acceptable salt thereof, which are useful for treating or preventing cancer.

  这项发明提供了具有结构的化合物（I），其中G1、G2、G3、G4、A1、A2、Y1、Y2、L1、Z、e和f在此处定义，或其药用可接受盐，用于治疗或预防癌症。
• [EN] SUBSTITUTED FUSED AZINES AS KRAS G12D INHIBITORS<br/>[FR] AZINES FUSIONNÉES SUBSTITUÉES UTILISÉES EN TANT QU'INHIBITEURS DE KRAS G12D
  申请人：LILLY CO ELI

  公开号：WO2022261154A1

  公开（公告）日：2022-12-15

  The present invention provides compounds of the formula where R1, R2, R3, R4a, R4b, R4c, R5, R6, X, Y, and Z are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and pharmaceutically acceptable salts thereof for treating patients for cancer.

  本发明提供了式子中R1、R2、R3、R4a、R4b、R4c、R5、R6、X、Y和Z所描述的化合物，以及其药学上可接受的盐，以及使用这些化合物和药学上可接受的盐治疗癌症患者的方法。
• [EN] POLYCYCLIC FUSED RING DERIVATIVES AND USE THEREOF<br/>[FR] DÉRIVÉS DE CYCLES CONDENSÉS POLYCYCLIQUES ET LEUR UTILISATION
  申请人：JACOBIO PHARMACEUTICALS CO LTD

  公开号：WO2023046135A1

  公开（公告）日：2023-03-30

  Provided are K-Ras mutant protein inhibitors of formula (I), a composition containing the same and the use thereof.

  本文提供了式 (I) 的 K-Ras 突变蛋白抑制剂、含有该抑制剂的组合物及其用途。
• 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives and Uses thereof
  申请人：NOVARTIS AG

  公开号：US20220402904A1

  公开（公告）日：2022-12-22

  The present disclosure relates to compounds of formula (I′) and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the treatment of inherited blood disorders (e.g., hemoglobinopathies, e.g., beta-hemoglobinopathies), such as sickle cell disease and beta-thalassemia.